RAPP vs RCKT

Rapport Therapeutics, Inc. vs Rocket Pharmaceuticals, Inc. — Valuation Comparison 2026

RAPP

Biotechnology
Rapport Therapeutics, Inc.
Quality
4.2
out of 10
Value Trap
12
SAFE
Price
$39.49
Last close
Models
8/13
Active
VS

RCKT

Biotechnology
Rocket Pharmaceuticals, Inc.
Quality
4.6
out of 10
Value Trap
31
LOW
Price
$3.02
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType RAPP Fair ValueRAPP Upside RCKT Fair ValueRCKT Upside
Bayesian DCF Intrinsic $11.30 -71.4% $0.95 -68.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $3.93 -90.0% $1.19 -60.5%
Dynamic NAV Asset-Based $7.06 -82.1% $1.67 -44.6%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for RAPP vs RCKT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RAPP vs RCKT — Which Stock Is More Undervalued?

RCKT scores higher with a 4.6/10 quality rating vs RAPP's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Rapport Therapeutics, Inc. (RAPP) and Rocket Pharmaceuticals, Inc. (RCKT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RAPP currently trades at $39.49 with a QOC of 4.2/10, while RCKT trades at $3.02 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).